PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Sethunath, V.* ; Hu, H.* ; de Angelis, C.* ; Veeraraghavan, J.* ; Qin, L.* ; Wang, N.* ; Simon, L. ; Wang, T.* ; Fu, X.* ; Nardone, A.* ; Pereira, R.* ; Nanda, S.* ; Griffith, O.L.* ; Tsimelzon, A.* ; Shaw, C.* ; Chamness, G.C.* ; Reis-Filho, J.S.* ; Weigelt, B.* ; Heiser, L.M.* ; Hilsenbeck, S.G.* ; Huang, S.* ; Rimawi, M.F.* ; Gray, J.W.* ; Osborne, C.K.* ; Schiff, R.*

Targeting the mevalonate pathway to overcome acquired anti-HER2 treatment resistance in breast cancer.

Mol. Cancer Res. 17, 2318-2330 (2019)
Verlagsversion DOI PMC
Closed
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Despite effective strategies, resistance in HER2(+) breast cancer remains a challenge. While the mevalonate pathway (MVA) is suggested to promote cell growth and survival, including in HER2(+) models, its potential role in resistance to HER2-targeted therapy is unknown. Parental HER2(+) breast cancer cells and their lapatinib-resistant and lapatinib + trastuzumab-resistant derivatives were used for this study. MVA activity was found to be increased in lapatinib-resistant and lapatinib + trastuzumab-resistant cells. Specific blockade of this pathway with lipophilic but not hydrophilic statins and with the N-bisphosphonate zoledronic acid led to apoptosis and substantial growth inhibition of R cells. Inhibition was rescued by mevalonate or the intermediate metabolites farnesyl pyrophosphate or geranylgeranyl pyrophosphate, but not cholesterol. Activated Yes-associated protein (YAP)/transcriptional coactivator with PDZ-binding motif (TAZ) and mTORC1 signaling, and their downstream target gene product Survivin, were inhibited by MVA blockade, especially in the lapatinib-resistant/lapatinib + trastuzumab-resistant models. Overexpression of constitutively active YAP rescued Survivin and phosphorylated-S6 levels, despite blockade of the MVA. These results suggest that the MVA provides alternative signaling leading to cell survival and resistance by activating YAP/TAZ-mTORC1-Survivin signaling when HER2 is blocked, suggesting novel therapeutic targets. MVA inhibitors including lipophilic statins and N-bisphosphonates may circumvent resistance to anti-HER2 therapy warranting further clinical investigation.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
4.484
1.086
15
22
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Yap; Growth; Activation; Lapatinib; Promotes; Chemotherapy; Simvastatin; Reductase; Apoptosis; Transcription
Sprache englisch
Veröffentlichungsjahr 2019
HGF-Berichtsjahr 2019
ISSN (print) / ISBN 1541-7786
e-ISSN 1557-3125
Zeitschrift Molecular Cancer Research
Quellenangaben Band: 17, Heft: 11, Seiten: 2318-2330 Artikelnummer: , Supplement: ,
Verlag American Association for Cancer Research (AACR)
Verlagsort 615 Chestnut St, 17th Floor, Philadelphia, Pa 19106-4404 Usa
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Computational Biology (ICB)
POF Topic(s) 30205 - Bioengineering and Digital Health
Forschungsfeld(er) Enabling and Novel Technologies
PSP-Element(e) G-503800-001
DOI 10.1158/1541-7786.MCR-19-0756
WOS ID WOS:000494368800015
Scopus ID 85074018943
PubMed ID 31420371
Erfassungsdatum 2019-11-25
[➜Korrektur melden]